Belatacept Pharmacokinetic Trial in Renal Transplantation

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the pharmacokinetics and safety of belatacept in de novo renal transplant subjects treated with belatacept-based immunosuppressant medication

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Abatacept

Criteria

Inclusion Criteria:

• Recipient of a living or deceased donor kidney

• First or second transplant

• Men and women, including women of childbearing potential, 18 years and older

Exclusion Criteria:

• Panel reactive antibodies ≥ 30%

• Significant infection